ArticleTranslational lung cancer research2026
A retrospective cohort study integrating invasive mucinous adenocarcinoma into the IASLC grading system for lung adenocarcinoma.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current International Association for the Study of Lung Cancer (IASLC) grading system for invasive pulmonary adenocarcinoma excludes invasive mucinous adenocarcinoma (IMA) and mixed IMA, limiting its prognostic scope. We aimed to refine the IASLC grading system by incorporating IMA and mixed IMA, and to validate it in large-scale cohorts. Methods: This single-institutional study included 692 patients with stage I-III lung invasive adenocarcinoma from Shanghai Chest Hospital (training cohort) and 7,862 from the Surveillance, Epidemiology, and End Results (SEER) database (validation cohort). We introduced IMA and reclassified the IASLC grading system. Prognostic performance was assessed using Harrell C-index, time-dependent receiver operating characteristic (ROC) curves and areas under the curve (AUCs). Overall survival (OS) curves were estimated via the Kaplan-Meier method, with log-rank test for difference comparison. Results: Mucinous predominant tumors with <20% of high-grade patterns (solid, micro papillary, complex glandular patterns) were classified as the Grade 2 (moderately differentiated). The proposed expanded grading system demonstrated improved prognostic accuracy, with C-index and AUC values of 0.713 and 0.739 in the training cohort, and 0.707 and 0.742 in the validation cohort, respectively. The 5-year OS rates for Grade 1, Grade 2, and Grade 3 were 87.5%, 73.1%, and 55.5% in the training cohort (P<0.001), and 80.2%, 67.3%, and 60.0% in the validation cohort (P<0.001). The proposed expanded grading system demonstrated superior prognostic performance compared to the current IASLC grading system in both cohorts. Conclusions: The proposed expanded IASLC grading system was practical and prognostic for lung invasive adenocarcinoma, and the introduction of IMA could improve its applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.